拉武利祖马布和Efgartigimod在肌痛性硬化症:一个现实世界的研究

Frauke Stascheit¹, Carla Daiane Ferreira de Sousa¹, Annette Aigner¹+14

• ¹From the Department of Neurology with Experimental Neurology (F.S., S.L., M.S., M.H., P.D., L.M.G., S.H., A.M.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin; Neuroscience Clinical Research Center (F.S., S.L., M.S., M.H., P.D., L.M.G., S.H., A.M.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin; Department of Neurology with Institute of Translational Neurology (C.D.F.S., M.B., C.W.K., L.K., H.W., J.D.L.), University Hospital Münster; Institute of Biometry and Clinical Epidemiology (A.A.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Center for Stroke Research Berlin (A.A., M.S., A.M.), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Germany; Department of Immunology (K.L.), Hellenic Pasteur Institute; and 2nd Neurology Department (J.T.), School of Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece.